William Blair Investment Management LLC Has $176.56 Million Stake in Insulet Co. (NASDAQ:PODD)

William Blair Investment Management LLC trimmed its position in Insulet Co. (NASDAQ:PODD - Free Report) by 16.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 676,309 shares of the medical instruments supplier's stock after selling 133,214 shares during the period. William Blair Investment Management LLC owned about 0.96% of Insulet worth $176,564,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of PODD. Counterpoint Mutual Funds LLC purchased a new stake in Insulet during the 4th quarter worth $297,000. Cibc World Markets Corp lifted its holdings in Insulet by 46.1% in the fourth quarter. Cibc World Markets Corp now owns 13,851 shares of the medical instruments supplier's stock worth $3,616,000 after acquiring an additional 4,368 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its stake in Insulet by 2.3% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock valued at $552,000 after acquiring an additional 48 shares during the period. Globeflex Capital L P bought a new position in shares of Insulet during the fourth quarter valued at approximately $131,000. Finally, Natixis Advisors LLC raised its position in shares of Insulet by 33.8% during the 4th quarter. Natixis Advisors LLC now owns 44,371 shares of the medical instruments supplier's stock worth $11,584,000 after purchasing an additional 11,210 shares during the period.

Insider Activity

In related news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares of the company's stock, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.47% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PODD. Piper Sandler upped their price objective on Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Stifel Nicolaus boosted their target price on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a report on Friday, February 21st. JPMorgan Chase & Co. lifted their price objective on shares of Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a research note on Thursday, December 12th. Royal Bank of Canada began coverage on shares of Insulet in a research note on Thursday, March 6th. They set an "outperform" rating and a $340.00 price objective for the company. Finally, Wells Fargo & Company lifted their price objective on shares of Insulet from $305.00 to $322.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Insulet currently has a consensus rating of "Moderate Buy" and an average target price of $292.06.

Insulet Stock Performance

Insulet stock traded up $2.93 during trading hours on Friday, hitting $268.32. The stock had a trading volume of 1,299,442 shares, compared to its average volume of 689,067. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The company has a market cap of $18.84 billion, a PE ratio of 46.34, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company has a 50-day moving average of $272.11 and a two-hundred day moving average of $256.26.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million during the quarter, compared to analysts' expectations of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. On average, equities research analysts anticipate that Insulet Co. will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.